Product
BDB-001
Aliases
BDB-001 injection, BDB-001 Injection
5 clinical trials
4 indications
Indication
Hidradenitis SuppurativaIndication
COVID-19 PneumoniaIndication
ANCA-associated VasculitisIndication
COVID-19Clinical trial
A Multicenter, Randomized, Double-blind, Placebo Parallel-controlled, Phase I/II Study to Explore Safety and Efficacy of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2023-07-07
Clinical trial
A Multi-center, Open-label, Randomized Parallel Controlled Evaluation on the Efficacy and Safety of BDB-001 Injection in the Treatment of Progressive Severe COVID-19 in Phase II/IIIStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Multicenter, Randomized, Open-lable, Parallel-controlled, Phase I/II Trial to Study Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With ANCA-associated VasculitisStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Multicenter, Open-label, Phase II Study to Explore Efficacy and Safety of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis SuppurativaStatus: Completed, Estimated PCD: 2023-08-22
Clinical trial
A Phase Ib, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BDB-001 Injection in Patients With Novel Coronavirus (2019-nCoV) InfectionStatus: Terminated, Estimated PCD: 2020-04-14